MANCHESTER, England--(BUSINESS WIRE)--Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”) signs an agreement for Thermo Fisher Scientific to provide a £5 million investment in Premaitha.
Premaitha’s CE-marked, non-invasive prenatal screening (NIPT) product, the IONA® test, runs on Thermo Fisher’s two sequencing instruments, the Ion Proton and Ion Chef. Thermo Fisher is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries.
